Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • steel.manof steel.manof Mar 19, 2013 12:13 PM Flag

    5 Fast Growers for Your Consideration ( SRPT ) article.

    Motley Fool
    5 Fast Growers for Your Consideration
    By Selena Maranjian | More Articles | Save For Later
    March 18, 2013 |
    Sarepta Therapeutics (NASDAQ: SRPT ) is developing the promising Duchenne muscular dystrophy drug eteplirsen, which may end up winning accelerated FDA approval. My colleague Brian Orelli has explained that the drug affects mRNAs by skipping the part of the gene that contain mutations and that "investors
    should keep an eye on RNA therapeutics given their potential to revolutionize medicine." Some wonder whether it will be bought out, while Wall Street's interest in the company is growing.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SRPT
31.76+0.16(+0.51%)Jul 30 4:00 PMEDT